New York, February 14, 2026, 15:34 EST — The market has closed.
- Thermo Fisher ended Friday at $504.82, slipping roughly 1%.
- The company disclosed in a filing that it’s raising $3.8 billion through senior notes, aiming to finance its planned Clario acquisition.
- U.S. markets stay closed Monday. Next up: retail sales data and the Fed minutes, both on investors’ radar.
Thermo Fisher Scientific Inc finished Friday’s session off almost 1%, settling at $504.82. According to a filing, the Waltham, Massachusetts company issued roughly $3.8 billion in new senior notes—corporate debt—to help fund its planned acquisition of clinical-trial data specialist Clario.
For investors, the focus isn’t so much on the notes as on what they indicate: Thermo Fisher is taking on new leverage while pushing to wrap up a sizable, regulator-sensitive deal—right as rates and risk appetite keep shifting.
Trading picks up again Tuesday after U.S. markets shut for Washington’s Birthday on Monday. It’s a packed week for U.S. data: retail sales hit Tuesday, and Fed minutes follow Wednesday. Both could jolt rate bets, even among typically steady healthcare names.
Thermo Fisher shares didn’t just stumble on Friday. On Thursday, the stock dropped 3.3% to $509.82, with volume surging to more than twice its 50-day average, MarketWatch reported. The S&P 500 slipped 1.6% that day as well.
Thermo Fisher detailed four separate note tranches in its offering documents, listing coupons from 4.215% up to 5.546% and maturities extending to 2046. Lead managers include Deutsche Bank, RBC, SMBC Nikko, and Wells Fargo. These notes are general unsecured obligations—not tied to any particular collateral.
Back in October, Thermo Fisher said it would acquire Clario in a deal valued at $8.875 billion in cash at close, with additional deferred and contingent payments on top. The company said it was targeting a completion by mid-2026, pending regulatory clearance.
Thermo Fisher trailed behind a few rivals on Friday. Danaher dropped 1.1% during the session, and the S&P 500 barely budged, according to MarketWatch data.
Bond financing isn’t always exciting, but it brings fresh questions to the table: what’s the pile of new debt going to look like, how close is the deal to wrapping up, and will management end up dialing back buybacks or other shareholder returns just to hold leverage steady?
There’s a straightforward risk here, too. According to a prospectus supplement, the Clario buyout isn’t a sure thing, and the offering doesn’t hinge on the deal closing. So, if regulators drag their feet or impose stricter terms, Thermo Fisher could be stuck with added debt on its books for longer than intended.
Eyes turn to Wednesday for the next signal on rate-related sentiment: the Federal Reserve will drop minutes from its January 27-28 meeting at 2:00 p.m. Eastern.
